Qiagen (NYSE:QGEN) Issues Q2 Earnings Guidance
Qiagen (NYSE:QGEN) issued an update on its second quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.33. The company issued revenue guidance of $381.6 million, compared to the consensus revenue estimate of $383.02 million.Qiagen also updated its FY19 guidance to ~$1.42-1.44 EPS.
NYSE:QGEN traded up $0.42 during midday trading on Friday, reaching $38.29. 974,077 shares of the stock traded hands, compared to its average volume of 716,992. Qiagen has a 12-month low of $32.33 and a 12-month high of $41.55. The firm has a 50-day moving average price of $39.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52. The company has a market cap of $8.54 billion, a PE ratio of 28.57, a PEG ratio of 2.36 and a beta of 0.84.
Qiagen (NYSE:QGEN) last posted its earnings results on Monday, May 6th. The company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.01. The company had revenue of $348.70 million during the quarter, compared to analysts’ expectations of $351.68 million. Qiagen had a net margin of 12.94% and a return on equity of 12.15%. Qiagen’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 earnings per share. Equities analysts forecast that Qiagen will post 1.41 EPS for the current year.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
See Also: Buy-Side Analysts
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.